Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minehiko Inomata

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Anticancer Research|February 29, 2024
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet ChemotherapyMinehiko Inomata, Shuhei Minatoyama, Naoki Takata, et al.
Cancer Diagnosis & Prognosis|May 5, 2025
Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy SpecimensMinehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, et al.
Molecular and Clinical Oncology|April 10, 2023
Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor‑infiltrating CD68‑positive cell counts in patients with EGFR‑mutant non‑small cell lung cancerTakeshi Tsuda, Kensuke Suzuki, Minehiko Inomata, et al.
Journal of Diabetes Investigation|May 21, 2014
Visceral adipose tissue level, as estimated by the bioimpedance analysis method, is associated with impaired lung functionMinehiko Inomata, Yukio Kawagishi, Chihiro Taka, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2017
[A Retrospective Study Analyzing the Clinical Course of Patients with Non-Small Cell Lung Cancer Receiving Local or Systemic Therapy after Post-Operative Recurrence]Minehiko Inomata, Hiroaki Tanaka, Kazuki Shimokawa, et al.
Respirology (Carlton, Vic.)|October 16, 2012
Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthmaTomomi Ichikawa, Ryuji Hayashi, Kensuke Suzuki, et al.
In Vivo (Athens, Greece)|April 30, 2024
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case ReportTakahiro Hirai, Minehiko Inomata, Shuhei Minatoyama, et al.
Internal Medicine (Tokyo, Japan)|December 22, 2011
A history of ischemic heart disease is a common cause of wheezing in the elderly of a Japanese local communityMinehiko Inomata, Yukio Kawagishi, Kotaro Tokui, et al.
Discover Oncology|August 29, 2024
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinomaTakeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, et al.
Thoracic Cancer|April 26, 2023
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practiceMinehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Anticancer Research|February 29, 2024
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet ChemotherapyMinehiko Inomata, Shuhei Minatoyama, Naoki Takata, et al.
Cancer Diagnosis & Prognosis|May 5, 2025
Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy SpecimensMinehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, et al.
Molecular and Clinical Oncology|April 10, 2023
Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor‑infiltrating CD68‑positive cell counts in patients with EGFR‑mutant non‑small cell lung cancerTakeshi Tsuda, Kensuke Suzuki, Minehiko Inomata, et al.
Journal of Diabetes Investigation|May 21, 2014
Visceral adipose tissue level, as estimated by the bioimpedance analysis method, is associated with impaired lung functionMinehiko Inomata, Yukio Kawagishi, Chihiro Taka, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2017
[A Retrospective Study Analyzing the Clinical Course of Patients with Non-Small Cell Lung Cancer Receiving Local or Systemic Therapy after Post-Operative Recurrence]Minehiko Inomata, Hiroaki Tanaka, Kazuki Shimokawa, et al.
Respirology (Carlton, Vic.)|October 16, 2012
Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthmaTomomi Ichikawa, Ryuji Hayashi, Kensuke Suzuki, et al.
In Vivo (Athens, Greece)|April 30, 2024
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case ReportTakahiro Hirai, Minehiko Inomata, Shuhei Minatoyama, et al.
Internal Medicine (Tokyo, Japan)|December 22, 2011
A history of ischemic heart disease is a common cause of wheezing in the elderly of a Japanese local communityMinehiko Inomata, Yukio Kawagishi, Kotaro Tokui, et al.
Discover Oncology|August 29, 2024
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinomaTakeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, et al.
Thoracic Cancer|April 26, 2023
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practiceMinehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, et al.
Pageof 7